anti-FAP/IL-12 TMEkine (Kanaph therapeutics/Yonsei University/Yonsei University College of Medicine)

N/A

Report date: 2025/01/26 18:47:39

Base Information

Drug Nameanti-FAP/IL-12 TMEkine (Kanaph therapeutics/Yonsei University/Yonsei University College of Medicine)
Drug Alias Nameantibody-cytokine fusion protein TMEkine (Kanaph therapeutics/Yonsei University/Yonsei University College of Medicine)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Monoclonal antibody conjugateBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody conjugateBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionFibroblast activation protein alpha inhibitorsInterleukin-12 receptor stimulants
TargetsInterleukin-12 receptorProlyl endopeptidase FAP
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySouth Korea
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesYonsei University
China Registration ClassN/A

Develop Information

Active CompaniesKanaph Therapeutics IncYonsei University
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A